Today: 30 June 2026
Browse Category

NASDAQ:TVTX 24 December 2025 - 13 January 2026

Ligand Pharmaceuticals stock slides as FDA pushes back Travere’s Filspari decision to April 13

Ligand Pharmaceuticals stock slides as FDA pushes back Travere’s Filspari decision to April 13

NEW YORK, Jan 13, 2026, 14:32 — Regular session Shares of Ligand Pharmaceuticals Incorporated dropped 10.6% to $184.80 in Tuesday afternoon trading. The decline followed an announcement from royalty partner Travere Therapeutics that U.S. regulators extended the review period for its Filspari application, pushing the decision date to April 13. Travere said the FDA classified its latest submission as a “major amendment” but didn’t request additional safety or manufacturing data. LGND shares opened at $196.96 and fluctuated between $175.89 and $206.78.
13 January 2026
···
Travere Therapeutics TVTX stock slides 5% as FDA decision on Filspari nears

Travere Therapeutics TVTX stock slides 5% as FDA decision on Filspari nears

New York, January 6, 2026, 15:27 — Regular session Nasdaq-listed Travere Therapeutics shares fell 5.3% to $36.09 in afternoon trading on Tuesday as investors looked toward next week’s U.S. FDA decision deadline on expanding its kidney drug Filspari into focal segmental glomerulosclerosis. The FDA’s Prescription Drug User Fee Act, or PDUFA, target action date is Jan. 13, and the stock has ranged from $34.88 to $39.16 in the session. SEC
6 January 2026
··
Travere Therapeutics (TVTX) Stock Watch: Pre‑Market Focus on the Jan. 13 FDA Decision After a 14% Rally

Travere Therapeutics (TVTX) Stock Watch: Pre‑Market Focus on the Jan. 13 FDA Decision After a 14% Rally

As of 8:54 a.m. ET in New York on Friday, December 26, 2025, U.S. markets are in pre‑market and set to reopen for the regular session at 9:30 a.m. ET. Travere Therapeutics, Inc. is entering the post‑holiday session with fresh momentum and a very specific catalyst on investors’ minds: an FDA decision deadline of January 13, 2026 for expanding FILSPARI into focal segmental glomerulosclerosis—a high‑stakes regulatory event that can move a biotech stock in either direction. Travere Therapeutics
26 December 2025
Travere Therapeutics (TVTX) Stock Jumps on Dec. 24, 2025: 52-Week High, FDA Catalyst Ahead, and Analyst Price Targets

Travere Therapeutics (TVTX) Stock Jumps on Dec. 24, 2025: 52-Week High, FDA Catalyst Ahead, and Analyst Price Targets

Travere Therapeutics, Inc. is ending 2025 with a bang. In the holiday-shortened U.S. trading session on Wednesday, December 24, 2025, TVTX surged sharply—pushing to fresh highs as investors recalibrated around two big themes: accelerating commercial execution for FILSPARI and a looming FDA decision that could expand the drug into a second major kidney disease indication. StockAnalysis+2New York Stock Exchange+2 In early trading on Dec. 24, TVTX was up roughly 15% and changing hands around the low $40 range—an outsized move for a single session, particularly during a day when markets closed early at 1:00 p.m. ET for Christmas Eve. StockAnalysis+2NASDAQ Trader+2
24 December 2025
·

Stock Market Today

  • ASX Ends Flat as Traders Await RBA Minutes
    June 29, 2026, 10:16 PM EDT. The Australian share market finished flat on the final trading day of the financial year. Investors kept to the sidelines ahead of the Reserve Bank of Australia's minutes, with traders looking for clues on the next policy steps amid economic uncertainty. Activity was muted, with mixed moves across sectors as the market took a cautious stance before the RBA's update on inflation and growth.
Go toTop